GlassScriptPhysician profile
Laura Rogers
NPI 1558872929
$5,391.43
in general payments reported to CMS, 2019-2025
35 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 91% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $687 · 2023: $1,065 · 2024: $1,417 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,394.87 | 2021-2025 | |
| Janssen Biotech, INC. | $575.42 | 2022-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $419.90 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $301.17 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $248.66 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $210.40 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $179.33 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $166.12 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $158.28 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $153.36 | 2023-2025 | Voquezna |
| Evoke Pharma, INC. | $147.49 | 2022-2025 | Gimoti |
| Celgene Corporation | $140.67 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $126.24 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $89.29 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $84.08 | 2024-2025 | Vegzelma |
| Astellas Pharma US INC | $80.37 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $76.10 | 2021 | |
| Aimmune Therapeutics, INC. | $65.22 | 2024-2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $65.15 | 2022-2023 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.22 | 2021 | |
| Viiv Healthcare Company | $56.17 | 2021 | |
| Mallinckrodt Hospital Products INC. | $54.65 | 2023-2025 | Terlivaz |
| Qol Medical, LLC | $54.02 | 2022-2023 | Sucraid |
| Pfizer INC. | $51.63 | 2021-2025 | |
| Abbott Laboratories | $26.33 | 2021 | |
| Daiichi Sankyo INC. | $26.31 | 2024 | Injectafer |
| Orphalan INC | $24.86 | 2025 | Cuvrior |
| Teva Pharmaceuticals USA, INC. | $23.26 | 2023 | Austedo Xr |
| Merck Sharp & Dohme LLC | $21.84 | 2023 | Dificid |
| Genzyme Corporation | $20.42 | 2025 | |
| Apria Healthcare LLC | $16.09 | 2021 | |
| Amgen INC. | $14.36 | 2023 | Avsola |
| Braintree Laboratories, INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.